Association Between the Expression of PD-L1 and the Therapeutic Efficacy of Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
Haigan · 20.04.2026 · 66 (2) · 49-54
DOI: 10.2482/haigan.66.49 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haigan, erschienen am 20.04.2026. Verfasst von Keisuke Shiraha und 9 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Shiraha, K., Watanabe, H., Goda, M., Matsuoka, S., Takigawa, Y., Nishimura, J., Kudo, K., Sato, K., Fujiwara, K., & Shibayama, T. (2026). Association Between the Expression of PD-L1 and the Therapeutic Efficacy of Osimertinib in EGFR-mutated Non-small Cell Lung Cancer. Haigan, 66(2), 49-54. https://doi.org/10.2482/haigan.66.49
Vancouver
Shiraha K, Watanabe H, Goda M, Matsuoka S, Takigawa Y, Nishimura J, et al. Association Between the Expression of PD-L1 and the Therapeutic Efficacy of Osimertinib in EGFR-mutated Non-small Cell Lung Cancer. Haigan. 2026;66(2):49-54. doi:10.2482/haigan.66.49
BibTeX
@article{Shiraha2026,
author = {Shiraha, Keisuke and Watanabe, Hiromi and Goda, Mayu and Matsuoka, Suzuka and Takigawa, Yuki and Nishimura, Jun and Kudo, Kenichiro and Sato, Ken and Fujiwara, Keiichi and Shibayama, Takuo},
title = {Association Between the Expression of PD-L1 and the Therapeutic Efficacy of Osimertinib in EGFR-mutated Non-small Cell Lung Cancer},
journal = {Haigan},
year = {2026},
volume = {66},
number = {2},
pages = {49--54},
doi = {10.2482/haigan.66.49}
}
EUVIMED